{"authors": [["Blackman", "Marcia A", "MA", "1 Trudeau Institute , Saranac Lake, New York."], ["Kim", "In-Jeong", "IJ", "1 Trudeau Institute , Saranac Lake, New York."], ["Lin", "Jr-Shiuan", "JS", "1 Trudeau Institute , Saranac Lake, New York."], ["Thomas", "Stephen J", "SJ", "2 Infectious Disease Division, Upstate Medical University, State University of New York , Syracuse, New York."]], "date": "2017-12-11", "id": "29227202", "text": "The emergence of outbreaks of Zika virus (ZIKV) in Brazil in 2015 was associated with devastating effects on fetal development and prompted a world health emergency and multiple efforts to generate an effective vaccine against infection. There are now more than 40 vaccine candidates in preclinical development and six in clinical trials. Despite similarities with other flaviviruses to which successful vaccines have been developed, such as yellow fever virus and Japanese Encephalitis virus, there are unique challenges to the development and clinical trials of a vaccine for ZIKV.", "doi": "10.1089/vim.2017.0145", "title": "Challenges of Vaccine Development for Zika Virus.", "journal": ["Viral immunology", "Viral Immunol."]}